<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: The Nocebo Response</title>
	<atom:link href="http://thehealthyskeptic.org/the-nocebo-response/feed/" rel="self" type="application/rss+xml" />
	<link>http://thehealthyskeptic.org/the-nocebo-response/</link>
	<description>Challenging mainstream dogma on nutrition, health and disease.</description>
	<pubDate>Sat, 22 Nov 2008 08:33:31 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: admin</title>
		<link>http://thehealthyskeptic.org/the-nocebo-response/#comment-81</link>
		<dc:creator>admin</dc:creator>
		<pubDate>Mon, 16 Jun 2008 14:04:34 +0000</pubDate>
		<guid isPermaLink="false">http://thehealthyskeptic.org/?p=34#comment-81</guid>
		<description>Thanks for your comment, Bruce.  I couldn't agree more that trials need better controls for both the placebo and nocebo effect.  

Some have argued (rightly, I believe) that an inert placebo control isn't enough, however, to guarantee a double-blind trial.  Patients taking the active drug in a study often experience side effects, which of course leads them to suspect they are taking the drug and not the placebo and ruins the blind.

A more accurate alternative would be an "active placebo", which is a substance that does not address the disease in question but has some relatively benign physiological effects like producing dry mouth or stimulation (like a caffeine pill, perhaps).  In studies done with active placebos, the difference between the efficacy of antidepressants and placebo was virtually nil.</description>
		<content:encoded><![CDATA[<p>Thanks for your comment, Bruce.  I couldn&#8217;t agree more that trials need better controls for both the placebo and nocebo effect.  </p>
<p>Some have argued (rightly, I believe) that an inert placebo control isn&#8217;t enough, however, to guarantee a double-blind trial.  Patients taking the active drug in a study often experience side effects, which of course leads them to suspect they are taking the drug and not the placebo and ruins the blind.</p>
<p>A more accurate alternative would be an &#8220;active placebo&#8221;, which is a substance that does not address the disease in question but has some relatively benign physiological effects like producing dry mouth or stimulation (like a caffeine pill, perhaps).  In studies done with active placebos, the difference between the efficacy of antidepressants and placebo was virtually nil.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Bruce</title>
		<link>http://thehealthyskeptic.org/the-nocebo-response/#comment-80</link>
		<dc:creator>Bruce</dc:creator>
		<pubDate>Mon, 16 Jun 2008 04:20:31 +0000</pubDate>
		<guid isPermaLink="false">http://thehealthyskeptic.org/?p=34#comment-80</guid>
		<description>I read about the nocebo effect recently in a scientific paper reviewing all the popular low-carb diet books. Two examples were given of studies comparing low-fat to low-carb diets. All subjects met with a dietitian several times, who probably reinforced the low-fat diet (placebo effect) and discouraged the low carb dieters (nocebo effect). This variable needs to be controlled. All subjects should be given reinforcement or none of them should.

http://www.scientificexploration.org/jse/articles/pdf/18.1_kauffman.pdf</description>
		<content:encoded><![CDATA[<p>I read about the nocebo effect recently in a scientific paper reviewing all the popular low-carb diet books. Two examples were given of studies comparing low-fat to low-carb diets. All subjects met with a dietitian several times, who probably reinforced the low-fat diet (placebo effect) and discouraged the low carb dieters (nocebo effect). This variable needs to be controlled. All subjects should be given reinforcement or none of them should.</p>
<p><a href="http://www.scientificexploration.org/jse/articles/pdf/18.1_kauffman.pdf" rel="nofollow">http://www.scientificexploration.org/jse/articles/pdf/18.1_kauffman.pdf</a></p>
]]></content:encoded>
	</item>
</channel>
</rss>
